Biomarkers for Alzheimer's Disease (AD) are critical for early diagnosis, tracking disease progression, and evaluating treatment efficacy. Key biomarkers include amyloid-beta (Aβ) plaques, tau protein tangles, and neurodegeneration indicators. Aβ plaques, detectable through cerebrospinal fluid (CSF) analysis and PET scans, signify early AD stages. Elevated levels of tau protein and phosphorylated tau in CSF correlate with neurofibrillary tangles, reflecting disease severity. Neurodegeneration markers, such as reduced glucose metabolism observed via FDG-PET scans and brain atrophy seen in MRI scans, indicate neuronal loss and cognitive decline. Novel blood-based biomarkers, including plasma Aβ and tau, offer non-invasive, cost-effective alternatives for widespread screening and monitoring. These advancements promise earlier intervention and improved management of AD and related dementias.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neuroimaging-based evaluation of scalp acupuncture for neural repair and reorganization in children with cerebral palsy
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Title : Neurophysiological change and cognitive response to levetiracetam in Alzheimer disease: Testing the missing mechanistic link
Christopher Hubler, Emergent Neural Systems Institute for Research, United States
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia